Dedicated view
After Conservative / Palliative Care
This view includes only public records whose official title or study scope explicitly states advanced, metastatic, recurrent, refractory, later-line, supportive care, or palliative. TrialBeacon makes no screening judgment, matching, or recommendation — it simply gathers the literally relevant official entries together and provides direct links to the originals. Whether a record is still open, or relevant to any individual situation, should be determined from the official original and your physician’s judgment.
Showing the verified snapshot of official records indexed on 2026-08-16. Every link opens the live original page.
Includes only public records whose official title explicitly mentions advanced / recurrent / later-line / supportive care. No recommendations, no matching — only links to the originals. Defer to the official page and your physician’s judgment.
Please read this first. A record appearing here does not mean it is open, available or appropriate for any individual. Inclusion is based only on wording in the official record — never on any judgement by this site. Discuss anything you find with your treating doctor.
Trial records retrieved live from the ClinicalTrials.gov public API.
Select the public official records you want to take to your appointment, then generate a list. Nothing is ranked or recommended — the list only reproduces titles and links.
Not signed in — up to 5 records per list. Sign in for higher free limits, or see Pro for more exports.
HTL0039732 in Participants With Advanced Solid Tumours
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
TLR9 Immunotherapy for Peritoneal Carcinomatosis
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
A Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for Metastatic Tumors (Colorectal Cancer, Gastric Cancer, and Hepatocellular Carcinoma)
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
PRE-ISPY Phase I/II Oncology Platform Program
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
A Study of PHN-012 in Patients With Advanced Solid Tumors
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
A Study Testing SOT109 for the First Time in Patients, to Assess How Safe SOT109 is, How Well it Works, and How the Body Handles it in Patients With Advanced Colorectal Cancer That Can Not be Removed by Surgery or is Metastatic
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Novel Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
ChiCTR — Chinese Clinical Trial Registry, public search
CTIS public register — search clinical trials authorised in the EU/EEA
ESMO Clinical Practice Guidelines — supportive and palliative care section
FDA — expanded access (compassionate use) information for patients
NCCN Guidelines — palliative care category listing
NCCN Guidelines for Patients — plain-language versions
药物临床试验登记与信息公示平台 — national registry of drug trials conducted in China
Whether a record is still open, current, or appropriate for any individual can only be confirmed by the official source and your treating doctor.
Ways to open the conversation with your doctor (reference only, not advice)
A template only — it teaches how to ask, and gives no answers. Adapt these to your own situation.
- Are these public records still searchable or open to enrolment?
- From the literal wording of the public titles, is there any point relevant to the current situation?
- If there is something relevant, what should I ask you about next?
- For symptoms, pain or supportive care, is there a public guideline worth prioritising as a reference?
These are only examples to help you start a conversation. They are not medical advice. All decisions should be made together with your treating doctor.